fda category 2 bulk drug substances bpc-157 compounding list just got voted in favor to be added to the 503A list, meaning a huge step towards being able to be prescribed and compounded in the US. Thank Regulatory Updates on Compounded Peptides

The otic formulations or compositions described herein are solution formulations or compositions

Endothelial potassium channels, endothelium-dependent hyperpolarization and the regulation of vascular tone in health and disease

Contraindications and Precautions Do NOT use AOD-9604 if you: Are pregnant, trying to conceive, or breastfeeding (no safety data in pregnancy/lactation) Have active cancer or history of malignancy (peptide effects on existing cancer unknown) Are under 18 years of age (pediatric safety not established) Have known hypersensitivity to peptides or benzyl alcohol (in bacteriostatic water) Have severe kidney or liver disease without physician clearance Use with caution and enhanced monitoring if you have: Diabetes or glucose metabolism disorders (monitor blood sugar closely despite no expected impact) Cardiovascular disease (comprehensive cardiac evaluation recommended) Thyroid disorders (monitor thyroid function during therapy) History of migraines (may increase headache frequency in susceptible individuals) Drug Interactions Limited formal drug interaction studies exist for AOD-9604

Current treatments are largely palliative and do not address the underlying fibrosis

However, the highest quantity of NMN dosage required to gain the NAD supplement benefit is 600 mg